Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Current Assets (2020 - 2025)

Historic Current Assets for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $15.5 million.

  • Evoke Pharma's Current Assets rose 1067.33% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year increase of 1067.33%. This contributed to the annual value of $17.2 million for FY2024, which is 15249.93% up from last year.
  • According to the latest figures from Q3 2025, Evoke Pharma's Current Assets is $15.5 million, which was up 1067.33% from $15.9 million recorded in Q2 2025.
  • Evoke Pharma's 5-year Current Assets high stood at $19.2 million for Q1 2021, and its period low was $6.8 million during Q4 2023.
  • Moreover, its 5-year median value for Current Assets was $12.5 million (2024), whereas its average is $12.9 million.
  • In the last 5 years, Evoke Pharma's Current Assets skyrocketed by 32307.44% in 2021 and then crashed by 5292.94% in 2022.
  • Evoke Pharma's Current Assets (Quarter) stood at $10.6 million in 2021, then increased by 11.0% to $11.7 million in 2022, then plummeted by 41.76% to $6.8 million in 2023, then skyrocketed by 152.5% to $17.2 million in 2024, then fell by 9.87% to $15.5 million in 2025.
  • Its Current Assets stands at $15.5 million for Q3 2025, versus $15.9 million for Q2 2025 and $16.2 million for Q1 2025.